Brexucabtagne Autoleucel's Efficacy in ALL: Bijal Shah, MD, MS
The associate member in the Department of Malignant Hematology at Moffitt Cancer Center discussed results of the ZUMA-3 trial.
This content originally appeared on our sister site, Targeted Oncology.
Targeted Oncology spoke with Bijal Shah, MD, MS, associate member, Department of Malignant Hematology, Moffitt Cancer Center, about the results of treatment with the chimeric antigen receptor (CAR) T-cell therapy brexucabtagne autoleucel (Tecartus) in the ZUMA-3 trial (NCT02614066) in patients with acute lymphoblastic leukemia (ALL).
Shah discussed his hope that he and his fellow investigators have done enough to show the FDA that this treatment is safe option to treat patients with ALL. Patients in the ZUMA-3 trial had a 71% complete remission (CR) rate with CAR T-cell therapy, which Shah says is unheard of in this population. These patients had progressed on previous therapies or after transplant. Patients achieved deep remissions and most had minimal residual disease negativity after treatment. These were real remissions, as opposed to cosmetic remissions, according to Shah.
This efficacy translated into pronounced benefits in relapse-free survival, duration of remission, and overall survival. Patients who achieved CR did not reach a median overall survival with CAR T. Shah feels that this is incredible for this patient population. CAR T-cell therapy was expected to be a meaningful treatment in ALL, and now the data show it can be used safely.
